Phase III,randomised, double‐blind,placebo‐controlled study of the β3‐adrenoceptor agonist mirabegron, 50 mg once daily,in Japanese patients with overactive bladder期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

Phase III,randomised, double‐blind,placebo‐controlled study of the β3‐adrenoceptor agonist mirabegron, 50 mg once daily,in Japanese patients with overactive bladder

Authors:	Osamu Yamaguchi Eiji Marui Hidehiro Kakizaki Yukio Homma Yasuhiko Igawa Masayuki Takeda Osamu Nishizawa Momokazu Gotoh Masaki Yoshida Osamu Yokoyama Narihito Seki Yasushi Ikeda Sumito Ohkawa

Affiliation:	1. Division of Bioengineering and LUTD Research, School of Engineering, Nihon University, , Koriyama, Japan;2. Department of Human Arts Sciences, University and Graduate School of Human Arts Sciences, , Saitama, Japan;3. Department of Urology, Asahikawa Medical University, , Asahikawa, Japan;4. Department of Urology, The University of Tokyo Graduate School of Medicine, , Tokyo, Japan;5. Department of Continence Medicine, The University of Tokyo Graduate School of Medicine, , Tokyo, Japan;6. Department of Urology, University of Yamanashi, , Yamanashi, Japan;7. Department of Urology, Shinshu University, , Matsumoto, Japan;8. Department of Urology, Nagoya University Graduate School of Medicine, , Nagoya, Japan;9. Department of Urology, National Center for Geriatrics and Gerontology, , Obu, Japan;10. Department of Urology, University of Fukui Faculty of Medical Sciences, , Fukui, Japan;11. Department of Urology, Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers, , Fukuoka, Japan;12. Astellas Pharma Inc., , Tokyo, Japan

Abstract:

Keywords:	β 3‐adrenoceptor agonist efficacy mirabegron overactive bladder safety

设为首页 | 免责声明 | 关于勤云 | 加入收藏